Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

NCT05694819 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

57

Enrollment

OTHER

Sponsor class

Conditions

Salivary Gland Cancer

Interventions

DRUG: Darolutamide
DRUG: Goserelin

Sponsor

National Cancer Center Hospital East

Collaborators

[object Object]